Investigation announced for Investors in HUTCHMED (China) Limited (NASDAQ: HCM) over potential Wrongdoing

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at HUTCHMED (China) Limited.

Investors who purchased shares of HUTCHMED (China) Limited (NASDAQ: HCM) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain HUTCHMED (China) Limited directors breached their fiduciary duties and caused damage to the company and its shareholders.

Hong Kong based HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally.
HUTCHMED (China) Limited reported that its annual Total Revenue rose from $227.97 million in 2020, to $356.12 million in 2021, and that its Net Loss increased from $125.73 million in 2020,, to $194.64 million in 2021.

On May 2, 2022, HUTCHMED (China) Limited announced that the U.S. Food and Drug Administration ("FDA") rejected Hutchmed's application seeking approval of surufatinib to treat certain neuroendocrine tumors, noting that the data submitted did not support an approval and a multi-regional clinical trial is required.

Shares of HUTCHMED (China) Limited (NASDAQ: HCM) declined to as low as $9.82 per share on May 10, 2022.

Those who purchased shares of HUTCHMED (China) Limited (NASDAQ: HCM) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.